Catalpol in Cardio-Cerebrovascular Disease Research
2026-09-12
This comprehensive review maps catalpol’s antioxidant, anti-inflammatory, and anti-apoptotic activities across major cardio-cerebrovascular disease settings and links them to pathways including PI3K/Akt, AMPK, Nrf2/HO-1, and PGC-1α/TERT. Its main practical value is an integrated framework connecting compound chemistry, pharmacokinetics, disease models, and translational limitations rather than a single therapeutic claim.
EGTA for Calcium Signaling and Neuroprotection
2026-09-12
EGTA, or egtazic acid, gives researchers a controllable way to lower extracellular free calcium while separating calcium-dependent signaling from receptor or channel activation. This guide translates cardiac vagal neuron electrophysiology into practical workflows for neuroprotection, calcium imaging, viability testing, and apoptosis assays, with emphasis on solubility, controls, and interpretation.
Bsa I (RNase-free): Practical DNA Cleavage Guide
2026-09-11
Bsa I (RNase-free), SKU K1095, provides sequence-directed type IIS DNA cleavage for gene cloning, DNA manipulation, and related molecular biology research workflows where RNA degradation should be minimized. It is intended for controlled scientific research only, not diagnostic, clinical, or medical use, and reaction conditions must be confirmed against the current product instructions.
Pyridostigmine, α-Bungarotoxin, and Placental Necroptosis
2026-09-11
The reference study identifies placental necroptosis as a modifiable component of preeclampsia-like pathology and shows that pyridostigmine improves several disease-associated outcomes in the RUPP rat model. Pharmacological blockade with α-bungarotoxin implicates α7 nicotinic acetylcholine receptor signaling in these effects, while hypoxic trophoblast experiments extend the mechanism to inflammation and cell migration.
CLCC1 and Herpesvirus Nuclear Egress
2026-09-10
A whole-genome CRISPR screen identified the host protein CLCC1 as essential for the membrane-fusion stage of herpesvirus nuclear egress. The findings connect herpesvirus capsid export with nuclear pore insertion and suggest an evolutionarily conserved cellular membrane-remodeling mechanism, while leaving the direct molecular role of CLCC1 unresolved.
Telmisartan: A Causal Benchmark for Cardiac Hypertrophy
2026-09-10
Telmisartan is an angiotensin II receptor antagonist that can serve as a receptor-proximal benchmark in cardiac hypertrophy experiments. This article contrasts AT1R blockade with RIP3/CaMKII biology and shows how to design assays that distinguish initiating signals from downstream remodeling.
Cabazitaxel Workflow for Resistant Cancer Models
2026-09-09
Cabazitaxel (XRP6258, SKU B2157) provides a practical taxane-based option for evaluating antiproliferative responses in P-glycoprotein-expressing and taxane-resistant cancer models. It is suited to controlled DMSO- or ethanol-based workflows, but is insoluble in water, and prepared solutions should be used promptly rather than stored long term.
ALDH2 Activation Delays Pressure-Overload Heart Failure
2026-09-08
A 2025 Experimental Cell Research study identifies ALDH2 activation as a way to extend the postnatal proliferative window of mouse cardiomyocytes and delay pressure-overload heart failure. The work positions Alda 1-based ALDH2 activation as a research strategy linking aldehyde detoxification, cardiomyocyte cell-cycle control, and cardiac remodeling, while leaving human translation and long-term regeneration unresolved.
Fosinopril Clinical Pharmacokinetics and Potential
2026-09-08
The 1997 review by Shionoiri and colleagues defined fosinopril’s clinical significance through its prodrug conversion, phosphinic acid-mediated ACE inhibition, and combined biliary and renal elimination of fosinoprilat. Its findings remain useful for interpreting blood pressure reduction, renal function, dialysis, hemodynamic effects, and drug-interaction evidence in hypertension research.
Dabigatran Etexilate: Oral Thrombin Inhibition
2026-09-07
The 2011 review by Blommel and Blommel presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States and explains how prodrug design addressed important limitations of warfarin and injectable anticoagulants. Its synthesis of pharmacology, pharmacokinetics, clinical efficacy, safety, and renal handling remains useful for interpreting thrombin inhibition mechanism studies and anticoagulant research.
Losartan: From AT1 Signaling to Matrix Biology
2026-09-05
Losartan is an angiotensin II receptor antagonist for dissecting AT1-driven vascular signaling, hypertension research, and cell-specific matrix remodeling. This article translates recent AGTR1 findings into a receptor-aware assay strategy that distinguishes vascular effects from tumor-microenvironment remodeling.
Angiotensin II: Mechanism and Research Protocols
2026-09-05
Angiotensin II is an endogenous octapeptide and potent vasopressor that activates angiotensin receptors to regulate vascular tone, aldosterone release, and inflammatory remodeling. Its defined receptor signaling and research-use protocols support hypertension mechanism studies, vascular smooth muscle cell hypertrophy research, and abdominal aortic aneurysm models.
Microglia, Synapses, and Alcohol-Induced Seizures
2026-09-04
The reference study identifies hippocampal microglial activation as a mechanistic link between acute alcohol exposure and increased seizure susceptibility. Its intervention-based design suggests that microglia influence both inhibitory and excitatory synapse formation in CA1, providing a framework for studying neuroimmune control of network excitability.
DIDS Workflows for Metastasis and Ion-Channel Studies
2026-09-04
DIDS links chloride-transport pharmacology with a practical near-death tumor-cell workflow for studying prometastatic states. This guide emphasizes formulation, dose selection, orthogonal controls, and interpretation across cancer, vascular, and TRPV1 models.
SAA–GOT2 Signaling in Doxorubicin Cardiotoxicity
2026-09-03
This 2025 study identifies GOT2, a mitochondrial enzyme in the malate-aspartate NADH shuttle, as a functional target of salvianolic acid A in doxorubicin-induced cardiotoxicity. Its integrated omics, biophysical, genetic, and animal-model evidence links GOT2-dependent redox metabolism with improved cardiac function, while also indicating that salvianolic acid A can preserve antitumor activity in a lung-cancer model.
484 records 7/33 page Previous Next First page 上5页 678910 下5页 Last page